MECOM and acute myeloid leukemia: In this setting also, treatment with a β-catenin/TCF signaling inhibitor, e.g., BC2059 (tegavivint), may not only reverse BET inhibitor resistance but also exhibit synergy with BET inhibitor against AML with inv(3)/t(3;3) and/or EVI1 overexpression90.